| Discovery Laboratories, Inc. | |||
| Proposed Ticker: | DSCO | 787 Seventh Avenue, 44th Floor | |
| Exchange: | NASDAQ-Small Cap Market | New York, NY 10019 | |
| Industry: | Service (SIC Code 8731) | (212) 554-4364 | |
| Type of Shares: | Common Shares | Filing Date: | 1/7/97 | |
| U.S. Shares Filed: | 12,101,409 | Filing Price: | $3.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $36,304,227 | |
| Primary Shares: | 0 | Expenses: | - | |
| Secondary Shares: | 12,101,409 | Shares Out After: | 12,101,409 |
| Manager | Tier | Phone |
| A Non Underwritten Offering | Lead Manager |
| Issuer's Law Firm: | Roberts, Sheridan & Kotel |
| Auditor: | Eisner, Richard A. |
| Registrar/Transfer Agent: | American Stock Transfer & Trust Co |
Dollar amounts in U.S. millions except for per share data | |||||
| 9 Month Ending Financials | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 9/30/96 | 9/30/95 | 11/8/96 | ||
| Revenue: | $0.00 | $0.00 | $0.00 | Assets: | $21.07 |
| Net Income: | -$0.02 | -$0.26 | -$0.02 | Curr Assets: | |
| EPS: | -$0.01 | -$0.07 | -$0.01 | Liabilities: | $2.40 |
| Prior EPS: | $0.00 | -$0.21 | $0.00 | Curr Liabilities: | |
| Cash Flow/Oper: | -$0.01 | Equity: | $18.67 | ||
| Cash Flow/Fin: | Cash: | ||||
| Cash Flow/Inv: | |||||
| Business Description |
| The company is a development stage pharmaceutical company that is focused on acquiring, developing and commercializing proprietary investigational drugs that have previously been tested in humans or animals. The company's strategy is to conduct preclinical and clinical studies on investigational drugs licensed from third parties, either on its own or in collaborations with corporate partners. the company may also seek to enter into collaborations with corporate partners for manufacturing and marketing of such drugs. The company currently has three licensed investigational drug candidates under development. 1) The company is developing SuperVent as a stable aerosolized, multidimensional therapy for airway diseases characterized by inflammation, injurious oxidation and excessive sputum. 2) KL(4)-Surfactant is a proprietary, synthetic lung surfactant invented at The Scripps Research Institute. 3) In October 1996, the company acquired an exclusive license from the Wisconsin Alumni Research Foundation relating to an active vitamin D analog, ST-630, and its potential use in treating postmenopausal osteoporosis. |
| Use of Proceeds |
| The proceeds from the proposed offering will be distributed to selling shareholders. |